5 |
Moon JI, Barbeito R, Faradji RN, et al. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up[J]. Transplantation, 2006, 82(12):1625-1628.
|
6 |
Bhat M, Usmani SE, Azhie A, et al. Metabolic consequences of solid organ transplantation[J]. Endocr Rev, 2021, 42(2):171-197.
|
7 |
Liang J, Lv C, Chen M, et al. Effects of preoperative hepatitis B virus infection, hepatitis C virus infection, and coinfection on the development of new-onset diabetes after kidney transplantation[J]. J Diabetes, 2019, 11(5):370-378.
|
8 |
Xu J, Xu L, Wei X, et al. Incidence and risk factors of posttransplantation diabetes mellitus in living donor kidney transplantation: a single-center retrospective study in China[J]. Transplant Proc, 2018, 50(10):3381-3385.
|
9 |
陈敏灵,张尧,于明香,等. 肾移植术后糖尿病的发病及其危险因素分析[J]. 中华内分泌代谢杂志,2013, 29(9):750-755.
|
10 |
Ling Q, Xu X, Xie H, et al. New-onset diabetes after liver transplantation: a national report from China Liver Transplant Registry[J]. Liver Int, 2016, 36(5):705-712.
|
11 |
Zhao T, Zhao Y, Zong A, et al. Association of body mass index and fasting plasma glucose concentration with post-transplantation diabetes mellitus in Chinese heart transplant recipients[J]. J Int Med Res, 2020, 48(3):300060520910629.
|
12 |
章保勇,胡盛寿,黄洁,等. 心脏移植受者移植后新发糖尿病的危险因素分析[J]. 中华器官移植杂志,2014, 35(4):221-224.
|
13 |
Eide IA, Halden TA, Hartmann A, et al. Mortality risk in post-transplantation diabetes mellitus based on glucose and HbA1c diagnostic criteria[J]. Transpl Int, 2016, 29(5):568-578.
|
14 |
Hackman KL, Snell GI, Bach LA. Poor glycemic control is associated with decreased survival in lung transplant recipients[J]. Transplantation, 2017, 101(9):2200-2206.
|
15 |
D′Avola D, Cuervas-Mons V, Martí J, et al. Cardiovascular morbidity and mortality after liver transplantation: the protective role of mycophenolate mofetil[J]. Liver Transpl, 2017, 23(4):498-509.
|
16 |
Roccaro GA, Goldberg DS, Hwang WT, et al. Sustained posttransplantation diabetes is associated with long-term major cardiovascular events following liver transplantation[J]. Am J Transplant, 2018, 18(1):207-215.
|
17 |
Shivaswamy V, Boerner B, Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes[J]. Endocr Rev, 2016, 37(1):37-61.
|
18 |
Feng KY, Henricksen EJ, Wayda B, et al. Impact of diabetes mellitus on clinical outcomes after heart transplantation[J]. Clin Transplant, 2021, 35(11):e14460.
|
19 |
Kim HJ, Jung SH, Kim JJ, et al. New-onset diabetes mellitus after heart transplantation-incidence, risk factors and impact on clinical outcome[J]. Circ J, 2017, 81(6):806-814.
|
20 |
Vest AR, Cherikh WS, Noreen SM, et al. New-onset diabetes mellitus after adult heart transplantation and the risk of renal dysfunction or mortality[J]. Transplantation, 2022, 106(1):178-187.
|
21 |
Cho MS, Choi HI, Kim IO, et al. The clinical course and outcomes of post-transplantation diabetes mellitus after heart transplantation[J]. J Korean Med Sci, 2012, 27(12):1460-1467.
|
22 |
Moro JA, Martínez-Dolz L, Almenar L, et al. Impact of diabetes mellitus on heart transplant recipients[J]. Rev Esp Cardiol, 2006, 59(10):1033-1037.
|
23 |
Kirov H, Moschovas A, Caldonazo T, et al. Diabetes is an independent risk factor for cancer after heart and/or lung transplantation[J]. J Clin Med, 2022, 11(14): 4127.
|
24 |
Hackman KL, Bailey MJ, Snell GI, et al. Diabetes is a major risk factor for mortality after lung transplantation[J]. Am J Transplant, 2014, 14(2):438-445.
|
25 |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志,2021, 13(4):315-409.
|
26 |
Cheungpasitporn W, Thongprayoon C, Vijayvargiya P, et al. The risk for new-onset diabetes mellitus after kidney transplantation in patients with autosomal dominant polycystic kidney disease: a systematic review and meta-analysis[J]. Can J Diabetes, 2016, 40(6):521-528.
|
27 |
Shah T, Kasravi A, Huang E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation[J]. Transplantation, 2006, 82(12):1673-1676.
|
28 |
Fabrizi F, Martin P, Dixit V, et al. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies[J]. Am J Transplant, 2005, 5(10):2433-2440.
|
29 |
Prasad N, Gurjer D, Bhadauria D, et al. Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients?[J]. Nephrology (Carlton), 2014, 19(4):244-250.
|
30 |
Baid S, Cosimi AB, Farrell ML, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality[J]. Transplantation, 2001, 72(6):1066-1072.
|
31 |
Chen T, Jia H, Li J, et al. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies[J]. Transpl Int, 2009, 22(4):408-415.
|
32 |
Sabharwal S, Delgado-Borrego A, Chung RT. Extrahepatic hepatitis C virus after transplantation: diabetes and renal dysfunction[J]. Liver Transpl, 2008, 14 (Suppl 2):S51-S57.
|
33 |
Younossi Z, Stepanova M, Saab S, et al. The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17 000 HCV-infected transplant recipients[J]. Aliment Pharmacol Ther, 2015, 41(2):209-217.
|
34 |
Handisurya A, Kerscher C, Tura A, et al. Conversion from tacrolimus to cyclosporine a improves glucose tolerance in HCV-positive renal transplant recipients[J]. PLoS One, 2016, 11(1):e0145319.
|
35 |
Saliba F, Lakehal M, Pageaux GP, et al. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study[J]. Liver Transpl, 2007, 13(1):136-144.
|
36 |
Toshima T, Yoshizumi T, Inokuchi S, et al. Risk factors for the metabolic syndrome components of hypertension, diabetes mellitus, and dyslipidemia after living donor liver transplantation[J]. HPB (Oxford), 2020, 22(4):511-520.
|
1 |
Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrinol, 2019, 15(3):172-188.
|
2 |
Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003[J]. Transplantation, 2003, 75(10 Suppl):SS3-SS24.
|
3 |
Sharif A, Hecking M, de Vries AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions[J]. Am J Transplant, 2014, 14(9):1992-2000.
|
4 |
Porrini EL, Díaz JM, Moreso F, et al. Clinical evolution of post-transplant diabetes mellitus[J]. Nephrol Dial Transplant, 2016, 31(3):495-505.
|
37 |
Xue M, Lv C, Chen X, et al. Donor liver steatosis: a risk factor for early new-onset diabetes after liver transplantation[J]. J Diabetes Investig, 2017, 8(2):181-187.
|
38 |
Shaked A, Loza BL, Van Loon E, et al. Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes[J]. Nat Med, 2022, 28(5):999-1005.
|
39 |
Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects[J]. Ann Rheum Dis, 2009, 68(7):1119-1124.
|
40 |
Qi D, Rodrigues B. Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism[J]. Am J Physiol Endocrinol Metab, 2007, 292(3):E654-E667.
|
41 |
Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal[J]. J Am Soc Nephrol, 2004, 15(12):3233-3239.
|
42 |
Mourad G, Glyda M, Albano L, et al. Incidence of posttransplantation diabetes mellitus in de novo kidney transplant recipients receiving prolonged-release tacrolimus-based immunosuppression with 2 different corticosteroid minimization strategies: ADVANCE, a randomized controlled trial[J]. Transplantation, 2017, 101(8):1924-1934.
|
43 |
Chakkera HA, Kudva Y, Kaplan B. Calcineurin inhibitors: pharmacologic mechanisms impacting both insulin resistance and insulin secretion leading to glucose dysregulation and diabetes mellitus[J]. Clin Pharmacol Ther, 2017, 101(1):114-120.
|
44 |
Pereira MJ, Palming J, Rizell M, et al. Cyclosporine A and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents[J]. J Clin Endocrinol Metab, 2014, 99(10):E1885-E1894.
|
45 |
Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus[J]. Am J Transplant, 2007, 7(6):1506-1514.
|
46 |
Torres A, Hernández D, Moreso F, et al. Randomized controlled trial assessing the impact of tacrolimus versus cyclosporine on the incidence of posttransplant diabetes mellitus[J]. Kidney Int Rep, 2018, 3(6):1304-1315.
|
47 |
Wissing KM, Abramowicz D, Weekers L, et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation[J]. Am J Transplant, 2018, 18(7):1726-1734.
|
48 |
Liu J, Liu D, Li J, et al. Efficacy and safety of everolimus for maintenance immunosuppression of kidney transplantation: a meta-analysis of randomized controlled trials[J]. PLoS One, 2017, 12(1):e0170246.
|
49 |
Jones-Hughes T, Snowsill T, Haasova M, et al. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model[J]. Health Technol Assess, 2016, 20(62):1-594.
|
50 |
Crepin T, Carron C, Roubiou C, et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients[J]. Am J Transplant, 2015, 15(4):1028-1038.
|
51 |
Baker D, Herrod SS, Alvarez-Gonzalez C, et al. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab[J]. JAMA Neurol, 2017, 74(8):961-969.
|
52 |
Zheng J, Song W. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: a systematic review and meta-analysis of randomized controlled trials[J]. Medicine (Baltimore), 2017, 96(28):e7151.
|
53 |
Setoguchi R, Hori S, Takahashi T, et al. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization[J]. J Exp Med, 2005, 201(5):723-735.
|
54 |
Aaseb- W, Midtvedt K, Valderhaug TG, et al. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab[J]. Nephrol Dial Transplant, 2010, 25(4):1289-1293.
|
55 |
Axelrod DA, Cheungpasitporn W, Bunnapradist S, et al. Posttransplant diabetes mellitus and immunosuppression selection in older and obese kidney recipients[J]. Kidney Med, 2022, 4(1):100377.
|
56 |
Saliba F, Rostaing L, Gugenheim J, et al. Corticosteroid-sparing and optimization of mycophenolic acid exposure in liver transplant recipients receiving mycophenolate mofetil and tacrolimus: a randomized, multicenter study[J]. Transplantation, 2016, 100(8):1705-1713.
|
57 |
Schweer T, Gwinner W, Scheffner I, et al. High impact of rejection therapy on the incidence of post-transplant diabetes mellitus after kidney transplantation[J]. Clin Transplant, 2014, 28(4):512-519.
|
58 |
Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: a systematic review of the literature[J]. Diabetes Care, 2002, 25(3):583-592.
|
59 |
Hjelmesaeth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation[J]. Diabetologia, 2004, 47(9):1550-1556.
|
60 |
Jiménez-Pérez M, González-Grande R, Omonte Guzmán E, et al. Metabolic complications in liver transplant recipients[J]. World J Gastroenterol, 2016, 22(28):6416-6423.
|
61 |
Lecronier M, Tashk P, Tamzali Y, et al. Gut microbiota composition alterations are associated with the onset of diabetes in kidney transplant recipients[J]. PLoS One, 2020, 15(1):e0227373.
|
62 |
Faucher Q, Jardou M, Brossier C, et al. Is Intestinal dysbiosis-associated with immunosuppressive therapy a key factor in the pathophysiology of post-transplant diabetes mellitus?[J]. Front Endocrinol (Lausanne), 2022, 13:898878.
|
63 |
van der Burgh AC, Moes A, Kieboom B, et al. Serum magnesium, hepatocyte nuclear factor 1β genotype and post-transplant diabetes mellitus: a prospective study[J]. Nephrol Dial Transplant, 2020, 35(1):176-183.
|
64 |
Schwaiger E, Krenn S, Kurnikowski A, et al. Early postoperative basal insulin therapy versus standard of care for the prevention of diabetes mellitus after kidney transplantation: a multicenter randomized trial[J]. J Am Soc Nephrol, 2021, 32(8):2083-2098.
|
65 |
Dos Santos Q, Hornum M, Terrones-Campos C, et al. Posttransplantation diabetes mellitus among solid organ recipients in a danish cohort[J]. Transpl Int, 2022, 35:10352.
|
66 |
Iqbal A, Zhou K, Kashyap SR, et al. Early post-renal transplant hyperglycemia[J]. J Clin Endocrinol Metab, 2022, 107(2):549-562.
|
67 |
Conte C, Maggiore U, Cappelli G, et al. Supporting physicians in the management of metabolic alterations in adult kidney transplant recipients: a comment on the joint position statement of the Italian Society of Nephrology (SIN), the Italian Society for Organ Transplantation (SITO) and the Italian Diabetes Society (SID)[J]. J Nephrol, 2020, 33(5):887-893.
|
68 |
Ussif AM, Åsberg A, Halden T, et al. Validation of diagnostic utility of fasting plasma glucose and HbA1c in stable renal transplant recipients one year after transplantation[J]. BMC Nephrol, 2019, 20(1):12.
|
69 |
Yates CJ, Fourlanos S, Colman PG, et al. Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation[J]. Nephrol Dial Transplant, 2014, 29(3):698-705.
|
70 |
Burt MG, Roberts GW, Aguilar-Loza NR, et al. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD[J]. J Clin Endocrinol Metab, 2011, 96(6):1789-1796.
|
71 |
Aouad LJ, Clayton P, Wyburn KR, et al. Evolution of glycemic control and variability after kidney transplant[J]. Transplantation, 2018, 102(9):1563-1568.
|
72 |
Yates CJ, Fourlanos S, Colman PG, et al. Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin[J]. Transplantation, 2013, 96(8):726-731.
|
73 |
L.凯萨琳·马汉. Krause营养诊疗学(第13版)[M]. 杜寿玢,陈伟,译. 北京:人民卫生出版社,2017.
|
74 |
中华医学会糖尿病学分会. 中国血糖监测临床应用指南(2021年版)[J]. 中华糖尿病杂志,2021, 13(10):936-948.
|
75 |
Chowdhury TA, Wahba M, Mallik R, et al. Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation[J]. Diabet Med, 2021, 38(6):e14523.
|
76 |
Von Visger JR, Gunay Y, Andreoni KA, et al. The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression[J]. Clin Transplant, 2014, 28(8):845-854.
|
77 |
Vest LS, Koraishy FM, Zhang Z, et al. Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: a retrospective analysis of integrated registry and pharmacy claims data[J]. Clin Transplant, 2018, 32(8):e13302.
|
78 |
Ram E, Lavee J, Tenenbaum A, et al. Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation[J]. Cardiovasc Diabetol, 2019, 18(1):118.
|
79 |
Haidinger M, Werzowa J, Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation-a randomized, double-blind, placebo-controlled trial[J]. Am J Transplant, 2014, 14(1):115-123.
|
80 |
Gueler I, Mueller S, Helmschrott M, et al. Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation[J]. Drug Des Devel Ther, 2013, 7:297-303.
|
81 |
Strøm Halden TA, Åsberg A, Vik K, et al. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation[J]. Nephrol Dial Transplant, 2014, 29(4):926-933.
|
82 |
Boerner BP, Miles CD, Shivaswamy V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation[J]. Int J Endocrinol, 2014:617638.
|
83 |
Bae J, Lee MJ, Choe EY, et al. Effects of dipeptidyl peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: a pilot study[J]. Endocrinol Metab (Seoul), 2016, 31(1):161-167.
|
84 |
Soliman AR, Fathy A, Khashab S, et al. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant[J]. Exp Clin Transplant, 2013, 11(6):494-498.
|
85 |
Guardado-Mendoza R, Cázares-Sánchez D, Evia-Viscarra ML, et al. Linagliptin plus insulin for hyperglycemia immediately after renal transplantation: a comparative study[J]. Diabetes Res Clin Pract, 2019, 156:107864.
|
86 |
Haidinger M, Antlanger M, Kopecky C, et al. Post-transplantation diabetes mellitus: evaluation of treatment strategies[J]. Clin Transplant, 2015, 29(5):415-424.
|
87 |
Türk T, Pietruck F, Dolff S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation[J]. Am J Transplant, 2006, 6(4):842-846.
|
88 |
Kajosaari LI, Niemi M, Neuvonen M, et al. Cyclosporine markedly raises the plasma concentrations of repaglinide[J]. Clin Pharmacol Ther, 2005, 78(4):388-399.
|
89 |
Luther P, Baldwin D Jr. Pioglitazone in the management of diabetes mellitus after transplantation[J]. Am J Transplant, 2004, 4(12):2135-2138.
|
90 |
Werzowa J, Hecking M, Haidinger M, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial[J]. Transplantation, 2013, 95(3):456-462.
|
91 |
Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications[J]. Circulation, 2016, 134(10):752-772.
|
92 |
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377(7):644-657.
|
93 |
Rajasekeran H, Kim SJ, Cardella CJ, et al. Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series[J]. Diabetes Care, 2017, 40(7):e75-e76.
|
94 |
Mahling M, Schork A, Nadalin S, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus[J]. Kidney Blood Press Res, 2019, 44(5):984-992.
|
95 |
Song CC, Brown A, Winstead R, et al. Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients[J]. Endocrinol Diabetes Metab, 2021, 4(2):e00185.
|
96 |
Muir CA, Greenfield JR, MacDonald PS. Empagliflozin in the management of diabetes mellitus after cardiac transplantation[J]. J Heart Lung Transplant, 2017, 36(8):914-916.
|
97 |
Cehic MG, Muir CA, Greenfield JR, et al. Efficacy and safety of empagliflozin in the management of diabetes mellitus in heart transplant recipients[J]. Transplant Direct, 2019, 5(5):e450.
|
98 |
Schwaiger E, Burghart L, Signorini L, et al. Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety[J]. Am J Transplant, 2019, 19(3):907-919.
|
99 |
Halden T, Kvitne KE, Midtvedt K, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus[J]. Diabetes Care, 2019, 42(6):1067-1074.
|
100 |
Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet Diabetes Endocrinol, 2019, 7(10):776-785.
|
101 |
Vanhove T, Remijsen Q, Kuypers D, et al. Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus[J]. Transplant Rev (Orlando), 2017, 31(2):69-77.
|
102 |
Singh P, Taufeeq M, Pesavento TE, et al. Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: a retrospective study[J]. Diabetes Obes Metab, 2020, 22(5):879-884.
|
103 |
Halden TA, Egeland EJ, Åsberg A, et al. GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes[J]. Diabetes Care, 2016, 39(4):617-624.
|
104 |
Liou JH, Liu YM, Chen CH. Management of diabetes mellitus with glucagonlike peptide-1 agonist liraglutide in renal transplant recipients: a retrospective study[J]. Transplant Proc, 2018, 50(8):2502-2505.
|
105 |
Singh P, Pesavento TE, Washburn K, et al. Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients [J]. Diabetes Obes Metab, 2019, 21(4): 1061-1065.
|
106 |
Stephen J, Anderson-Haag TL, Gustafson S, et al. Metformin use in kidney transplant recipients in the United States: an observational study[J]. Am J Nephrol, 2014, 40(6):546-553.
|
107 |
Aleksic S, Eisenberg R, Tsomos E, et al. Glycemic management and clinical outcomes in underserved minority kidney transplant recipients with type 2 and posttransplantation diabetes: a single-center retrospective study[J]. Diabetes Res Clin Pract, 2020, 165:108221.
|
108 |
Sanyal D, Biswas M, Chaudhari N. Long-term efficacy and safety of anti-hyperglycaemic agents in new-onset diabetes after transplant: Results from outpatient-based 1-year follow-up and a brief review of treatment options[J]. Diabetes Metab Syndr, 2021, 15(1):13-19.
|
109 |
Voytovich MH, Haukereid C, Hjelmesaeth J, et al. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients[J]. Clin Transplant, 2007, 21(2):246-251.
|
110 |
Raven LM, Muir CA, Kessler Iglesias C, et al. Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial[J]. BMJ Open, 2023, 13(3):e069641.
|
111 |
Dziodzio T, Biebl M, Öllinger R, et al. The role of bariatric surgery in abdominal organ transplantation-the next big challenge?[J]. Obes Surg, 2017, 27(10):2696-2706.
|
112 |
Hadjievangelou N, Kulendran M, McGlone ER, et al. Is bariatric surgery in patients following renal transplantation safe and effective? A best evidence topic[J]. Int J Surg, 2016, 28:191-195.
|
113 |
Schindel H, Winkler J, Yemini R, et al. Survival benefit in bariatric surgery kidney recipients may be mediated through effects on kidney graft function and improvement of co-morbidities: a case-control study[J]. Surg Obes Relat Dis, 2019, 15(4):621-627.
|
114 |
Hecking M, Haidinger M, D-ller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation[J]. J Am Soc Nephrol, 2012, 23(4):739-749.
|
115 |
American Diabetes Association Professional Practice Committee.16. Diabetes care in the hospital: standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1):S244-S253.
|
116 |
Lo C, Toyama T, Oshima M, et al. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients[J]. Cochrane Database Syst Rev, 2020, 8(8):CD009966.
|
117 |
Xia M, Yang H, Tong X, et al. Risk factors for new-onset diabetes mellitus after kidney transplantation: a systematic review and meta-analysis[J]. J Diabetes Investig, 2021, 12(1):109-122.
|
118 |
Cai R, Wu M, Xing Y. Pretransplant metabolic syndrome and its components predict post-transplantation diabetes mellitus in Chinese patients receiving a first renal transplant[J]. Ther Clin Risk Manag, 2019, 15:497-503.
|
119 |
Adams LA, Arauz O, Angus PW, et al. Additive impact of pre-liver transplant metabolic factors on survival post-liver transplant[J]. J Gastroenterol Hepatol, 2016, 31(5):1016-1024.
|
120 |
Bergrem HA, Valderhaug TG, Hartmann A, et al. Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy[J]. Clin J Am Soc Nephrol, 2010, 5(4):616-622.
|
121 |
Ishikawa S, Tasaki M, Ikeda M, et al. Pretransplant BMI should be<25 in Japanese kidney transplant recipients: a single-center experience[J]. Transplant Proc, 2023, 55(1):72-79.
|
122 |
Bambha KM, Dodge JL, Gralla J, et al. Low, rather than high, body mass index confers increased risk for post-liver transplant death and graft loss: risk modulated by model for end-stage liver disease[J]. Liver Transpl, 2015, 21(10):1286-1294.
|
123 |
Kim DG, Kim BS, Choi HY, et al. Association between post-transplant uric acid level and renal allograft fibrosis: analysis using Banff pathologic scores from renal biopsies[J]. Sci Rep, 2018, 8(1):11601.
|
124 |
Kittleson MM, Bead V, Fradley M, et al. Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients[J]. J Heart Lung Transplant, 2007, 26(5):498-503.
|
125 |
Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients[J]. Transplantation, 2007, 83(8):1027-1034.
|